P
GSK icon

Pitcairn’s GSK GSK Stock Holding History

Pitcairn’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,576
Closed -$370K – 235
2025
Q3 		$370K Sell
8,576
-1,081
-11% -$42.2K 0.03% 437
2025
Q2 		$371K Sell
9,657
-2,700
-22% -$103K 0.02% 490
2025
Q1 		$479K Buy
12,357
+2,429
+24% +$88.9K 0.03% 436
2024
Q4 		$336K Buy
9,928
+1,828
+23% +$65.8K 0.02% 552
2024
Q3 		$331K Sell
8,100
-1,328
-14% -$54.3K 0.02% 560
2024
Q2 		$363K Buy
9,428
+434
+5% +$18.3K 0.02% 532
2024
Q1 		$386K Buy
8,994
+1,281
+17% +$52.8K 0.03% 500
2023
Q4 		$286K Buy
+7,713
New +$277K 0.02% 554

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pitcairn's GSK Position: Q4 2025 in Review

Pitcairn sold out of GSK (GSK) in Q4 2025, closing a stake of 8,576 shares — an estimated $370K sold.

Pitcairn first reported a position in GSK in Q4 2023 and held it in 8 quarters. The position peaked at $479K in Q1 2025. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Pitcairn reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 8,576 GSK shares in Q4 2025, an estimated $370K.
  • Pitcairn first reported a position in GSK in Q4 2023 and held it in 8 quarters.
  • Pitcairn's GSK position peaked at $479K in Q1 2025.
  • 995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.